Contingent Value Right (CVR)
-
Pfizer, Metsera Amend Merger Agreement; Metsera Board Reaffirms Support
Metsera Inc. has announced an amended merger agreement with Pfizer, valued at up to $86.25 per share, comprising $65.60 upfront and a contingent value right (CVR) of up to $20.65 based on milestones. The Metsera Board unanimously recommends shareholder approval, citing optimal value and deal certainty. This decision follows concerns raised by the U.S. Federal Trade Commission regarding a previous deal with Novo Nordisk. The board prioritizes the Pfizer merger due to its expectation of swift closure and immediate value delivery to shareholders.
